The company recently added a five-head isolator filler, designed for fill-finish activities, with the potential to generate up to $300 million in revenue annually.
The specialized $41.2 million facility will support production of viral vectors for cell and gene therapies to treat certain cancers and autoimmune and genetic diseases.
